对1型糖尿病的多学科方法:技术,免疫疗法和个性化医学的交集
Denisa Batir-Marin1, Claudia Simona Ștefan2, Monica Boev1
1Department of Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University, 800008 Galati, Romania.
Journal of clinical medicine
|April 12, 2025
概括
数字健康和再生医学的进步正在改变1型糖尿病 (T1D) 管理. 持续血糖监测,人工智能和干细胞治疗方面的创新为改善血糖控制和疾病修饰提供了新的希望.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 1型糖尿病 (T1D) 是一种自身免疫性疾病,导致胰腺β细胞破坏和胰岛素缺乏.
- 尽管有进展,目前的疗法仍在努力实现最佳的血糖控制.
- 新的技术和治疗方法正在出现,以改善T1D管理.
研究的目的:
- 审查最近1型糖尿病治疗方面的进展.
- 探索数字健康,生物医学方法和纳米医学方面的创新.
- 评估这些策略在改善患者治疗结果方面的潜力.
主要方法:
- 关于T1D治疗创新的最新文献的综述.
- 专注于持续血糖监测 (CGM),自动胰岛素输送,人工智能,远程医疗,干细胞治疗,基因编辑,免疫治疗和纳米医学.
- 对技术和生物医学干预措施的研究结果的综合.
主要成果:
- 像CGM和AI这样的数字健康工具显著改善了葡萄糖管理和个性化护理.
- 再生医学 (干细胞,基因编辑) 和免疫疗法显示出疾病修饰的潜力.
- 微生物组调节和纳米医学为代谢调节和氧化应激提供了新的方法.
结论:
- T1D管理的未来在于精密医学和综合技术解决方案.
- 再生医学,人工智能和纳米技术提供了有前途的治疗途径.
- 解决有效性,安全性,可访问性和验证方面的挑战对于临床翻译至关重要.
相关概念视频
Diabetes: Management and Pharmacotherapy
213
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
213
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Autoimmune Disorders
325
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
325
Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406
Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127


